Ten stocks rose on Monday, outperforming a mixed performance among Wall Street’s major indices, as investors digested a flurry of catalysts, including corporate earnings and the agreed-upon trade deal between the US and the European Union.

Among Wall Street’s main indices, only the Nasdaq and S&P 500 finished in the green, up 0.33 percent and 0.02 percent, respectively. The Dow Jones was down by 0.14 percent.

In this article, we highlight the names of the 10 best-performing stocks and detail the reasons behind their gains.

To compile the list, we focused on stocks with more than $300 million in capitalization and 5 million shares in trading volume.

10. Patterson-UTI Energy, Inc. (NASDAQ:PTEN)

Patterson-UTI bounced back by 5.41 percent on Monday to close at $6.24 apiece as investors loaded up positions following a two-day drop dragged by dismal earnings performance.

During the period, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) said it swung to a net loss attributable to shareholders of $49 million from an $11 million net income in the same period last year, as revenues dropped by 7 percent to $1.2 billion from $1.3 billion year-on-year.

The performance was largely dampened by increasing oil market volatility during the quarter, driven by evolving trade policies, among others.

For the six-month figure, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also reversed a $62-million net income attributable to shareholders last year after booking a $48-million net loss in the first half of the year. Revenues were lower by 10.7 percent to $2.5 billion from $2.8 billion year-on-year.

Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also declared a $0.08 dividend to shareholders as of September 2, payable on September 15.

9. Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports that it was set to be acquired by a Japan-based pharmaceutical company.

According to a post by @rumourbuyouts on X, pharmaceutical firm Otsuka is said to be in talks to fully acquire Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a deal that could potentially be valued $900 million. The post added that the two companies are set to meet in August to discuss a deal.

Based on the social media handle, @rumourbuyouts is currently based in Japan and only has 177 followers.

Meanwhile, Esperion Therapeutics, Inc. (NASDAQ:ESPR) said that it is scheduled to release the results of its second quarter earnings performance before market open on August 5, Tuesday.

8. Ardagh Metal Packaging SA (NYSE:AMBP)

Ardagh Metal bounced back from two days of losses on Monday, jumping 6.38 percent to close at $4 apiece as investors cheered a massive recapitalization program that will see the company being taken over by new major shareholders.

In a statement, Ardagh Metal Packaging SA (NYSE:AMBP) said that the transaction involves a debt-to-equity conversion of some $4.3 billion in obligations to creditors of its existing senior unsecured notes (SUN) and senior secured toggle (PIK) notes.

Effectively, SUN creditors will become the majority shareholders of the group, receiving 92.5 percent of equity, while the remaining 7.5 percent will represent the PIK holders.

The transaction also involves a provision for $1.5 billion in new capital and extension of existing bond maturities, among others.

Ardagh Metal Packaging SA (NYSE:AMBP) said that the transaction is expected to effectively reduce its debt burden.

Ardagh Metal Packaging SA (NYSE:AMBP) said it expects to complete the transaction by September 30, 2025, subject to regulatory approvals and other customary conditions.

7. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Pacific Biosciences jumped by 6.49 percent on Monday to close at $1.64 apiece as investors began repositioning portfolios ahead of its second-quarter earnings release.

According to the company, it is scheduled to announce the results of its financial and operating highlights after market close on August 7, where investors will closely watch out for updates on its restructuring plan in a bid to reduce operating expenses by $45-$50 million by the end of the year. An investor call will be held on the same day to elaborate on the results.

In the first quarter of the year, Pacific Biosciences of California, Inc. (NASDAQ:PACB) widened its net loss by 446 percent to $426 million from $78 million in the same period last year, following a 429-percent expansion in operating loss.

Revenues amounted to $37.1 million, lower by 4.6 percent than the $38.8 million year-on-year.

6. PagerDuty, Inc. (NYSE:PD)

PagerDuty rallied for a second day on Monday, adding 7.06 percent to close at $16.83 apiece as investors took heart from an analyst upgrade and news that it was exploring a sale.

In its market note, investment firm TD Cowen raised its price target and recommendation for PagerDuty, Inc. (NYSE:PD) to $22 from $17 and to “buy” from “hold” previously.

This followed a report by Reuters on Friday, quoting sources privy to the matter, that PagerDuty, Inc. (NYSE:PD) was exploring a potential sale after receiving interest from buyers.

Reuters said PagerDuty, Inc. (NYSE:PD) is currently working with Qatalyst Partners to facilitate the potential acquisition, and that investment bankers are now soliciting further buyer interest.

According to TD Cowen, Qatalyst Partners has a strong track record of facilitating software mergers and acquisitions, adding that many of its facilitated transactions resulted in sales over the years.

PagerDuty, Inc. (NYSE:PD) is a California-based software maker that helps businesses monitor their IT systems and respond to cyber incidents and outages.

5. Kosmos Energy Ltd. (NYSE:KOS)

Kosmos Energy saw its share prices increase by 7.66 percent on Monday to close at $2.39 apiece as investors repositioned portfolios ahead of its earnings release next week.

According to the company, it is scheduled to release the results of its financial and operating highlights on August 4, 2025. An investor call will be held on the same day to elaborate on the results.

Based on its guidance announced earlier this year, Kosmos Energy Ltd. (NYSE:KOS) said it was targeting to produce between 66,000 and 72,000 barrels of oil per day (boe/d) for the second quarter of the year, and between 70,000 to 80,000 boe/d for full-year 2025. In the first quarter alone, the company was able to produce 60,500 boe/d.

Also in the first quarter, Kosmos Energy Ltd. (NYSE:KOS) swung to a net loss of $110.6 million from a $91.7 million net income in the same period last year.

Total revenues and other income ended at $290 million, lower by 31 percent than the $419 million in the same period last year.

4. Vor Biopharma Inc. (NASDAQ:VOR)

Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece and bucking the decline in the overall healthcare sector, as investors continued to load up positions following the addition of two CEOs in its board.

Early last week, Vor Biopharma Inc. (NASDAQ:VOR) announced the addition of Alexander Cumbo and Michel Detheux to its board of directors, sparking confidence among investors amid ongoing efforts to strengthen leadership and strategic direction.

Cumbo currently serves as president and CEO of Solid Biosciences. He was also the founding CEO of AavantiBio and brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta Therapeutics, where he most recently served as Executive Vice President and Chief Commercial Officer.

Meanwhile, Detheux is the president and CEO of iTeos Therapeutics. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s lead anti-TIGIT antibody.

In a statement, Vor Biopharma Inc. (NASDAQ:VOR) said that Cumbo and Detheux’s addition is invaluable as the company advances telitacicept through late-stage development and expands its long-term vision to bring transformative therapies to patients with autoimmune disease.

3. Super Micro Computer, Inc. (NASDAQ:SMCI)

Super Micro jumped for a fourth straight day on Monday, adding 10.24 percent to close at $60.05 apiece as investors cheered President Donald Trump’s decision to freeze export restrictions on technology products to China as Washington and Beijing resume trade negotiations.

The US and China will meet in Stockholm for a third round of trade talks on Monday, following previous meetings in Geneva and London.

Known for its AI-focused server systems, Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the companies benefiting from increased technology spending this year. Year-to-date, its stock has gone up by almost 100 percent as more companies globally build large artificial intelligence workloads.

In other developments, Super Micro Computer, Inc. (NASDAQ:SMCI) is set to announce the results of its earnings performance for the fourth quarter of fiscal year 2025 after market close on August 5. An investor call will be held on the same day to elaborate on the results.

2. SES AI Corporation (NYSE:SES)

SES AI jumped by 15.25 percent on Monday to close at $1.36 apiece as investors cheered its reaffirmation of growth guidance for full-year 2025 and release of preliminary earnings results.

In the second quarter of the year, SES AI Corporation (NYSE:SES) said it expects to report $3.5 million in revenues for the second quarter of the year, pushing its first-half revenue to $9.3 million.

The company is scheduled to release official results after market close on August 4, 2025, followed by a conference call later in the day.

Following the preliminary results, SES AI Corporation (NYSE:SES) affirmed its year-end revenue target of $15 million to $25 million.

In a separate statement, SES AI Corporation (NYSE:SES) announced plans to fully acquire energy storage systems provider UZ Energy for $25.5 million.

UZ Energy specializes in designing and manufacturing ESS products for commercial and industrial applications. It has deployed over 500 MWh of ESS safely in over 60 countries with zero incidents.

“AI data centers in the US are on track to triple their share of national electricity usage by 2028. This acquisition of UZ Energy launches us into this exciting market, accelerates our revenue growth, and strengthens our Molecular Universe’s ability to deliver better ESS battery materials and health monitoring systems by providing real-world data to train our models,” said SES AI Corporation (NYSE:SES) founder and CEO Qichao Hu.

1. Celcuity Inc. (NASDAQ:CELC)

Celcuity soared by 167 percent on Monday to close at $36.79 apiece as investors cheered positive results in its clinical trial for its breast cancer treatment candidate.

In a statement on Monday, Celcuity Inc. (NASDAQ:CELC) said it achieved positive topline results from the phase 3 clinical study of gedatolisib combined with palbociclib and fulvestrant—an experimental treatment for adults with two kinds of breast cancer.

Called the gedatolisib triple, the three-drug combination reduced risk progression and death by 76 percent as compared with taking fulvestrant alone.

Meanwhile, its gedatolisib double, which combines gedatolisib and fulvestrant, lowered the risk of progression and death by 67 percent, also achieving primary endpoints.

Celcuity Inc.’s (NASDAQ:CELC) clinical trial success bolsters its chances of filing an approval with the Food and Drug Administration by the fourth quarter of the year.

Following the results, Celcuity Inc. (NASDAQ:CELC) earned a whopping $60 price target from Leerink, a marked increase from the $28 target previously. It also maintained an “outperform” rating on its stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.